Skip to main content
رجوع
LYPHF logo

Luye Pharma Group Ltd.

جودة البيانات: 100%
ذروة شراء
LYPHF
OTC Healthcare Drug Manufacturers - General
KWD 0.38
KWD 0.00 (0.00%)
القيمة السوقية: 1.51B
نطاق اليوم
KWD 0.38 KWD 0.40
نطاق 52 أسبوعًا
KWD 0.26 KWD 0.40
حجم التداول
400
متوسط 50 يوم / 200 يوم
KWD 0.38 / KWD 0.32
الإغلاق السابق
KWD 0.38

Quick Summary

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (631 نظير)

المقياس السهم وسيط القطاع
P/E 3.2 0.2
P/B 0.1 3.0
ROE % 3.5 3.5
Net Margin % 7.8 3.8
Rev Growth 5Y % 2.3 9.7
D/E 0.7 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 KWD 0.27
KWD 0.25 – KWD 0.29
7.76B 1
FY2026 KWD 0.19
KWD 0.18 – KWD 0.20
6.96B 1

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2025-08-28 KWD 0.01 KWD 0.01 +18.8%
2025-03-27 KWD 0.02 KWD 0.00 -79.7%
2024-08-28 N/A KWD 0.01
2024-04-08 KWD 0.01 KWD 0.01 +1.9%
2023-06-30 KWD 0.00 KWD 0.01 +35.3%
2023-03-29 KWD 0.01 KWD 0.01 +48.4%
2022-08-29 KWD 0.02 KWD 0.01 -34.3%
2022-03-29 KWD 0.01 -KWD 0.02 -266.2%

Dividend History

2 yr streak

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

Ex-Date Payment Date Amount Yield
Jun 29, 2020 Jul 31, 2020 KWD 0.01 2.17%
Sep 09, 2019 Sep 30, 2019 KWD 0.01 2.25%
Jun 14, 2019 Jul 18, 2019 KWD 0.01 1.97%
Sep 06, 2018 Sep 28, 2018 KWD 0.01 1.78%
Jun 14, 2018 Jun 29, 2018 KWD 0.01 1.48%
Oct 04, 2017 Nov 08, 2017 KWD 0.00 1.23%
Jun 15, 2017 Jul 18, 2017 KWD 0.00 0.67%

النقاط الرئيسية

Revenue grew 2.28% annually over 5 years — modest growth
Earnings declined -11.40% over the past year
ROE of 3.54% is below average
Negative free cash flow of -1.54B
P/E of 3.20 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3.61%

النمو

Revenue Growth (5Y)
2.28%
Revenue (1Y)-1.33%
Earnings (1Y)-11.40%
FCF Growth (3Y)N/A

الجودة

Return on Equity
3.54%
ROIC3.96%
Net Margin7.79%
Op. Margin21.30%

الأمان

Debt / Equity
0.73
Current Ratio1.24
Interest Coverage2.30

التقييم

P/E Ratio
3.20
Forward P/E1.96
P/B Ratio0.11
EV/EBITDA5.34
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -1.33% Revenue Growth (3Y) 0.66%
Earnings Growth (1Y) -11.40% Earnings Growth (3Y) -11.67%
Revenue Growth (5Y) 2.28% Earnings Growth (5Y) -9.60%
Profitability
Revenue (TTM) 6.06B Net Income (TTM) 471.89M
ROE 3.54% ROA 1.59%
Gross Margin 66.72% Operating Margin 21.30%
Net Margin 7.79% Free Cash Flow (TTM) -1.54B
ROIC 3.96% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.73 Current Ratio 1.24
Interest Coverage 2.30
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years 2 yrs
Valuation
P/E Ratio 3.20 Forward P/E 1.96
P/B Ratio 0.11 P/S Ratio 0.25
PEG Ratio -0.23 Forward PEG N/A
EV/EBITDA 5.34 Fwd EV/EBITDA 2.21
Forward P/S 0.22 Fwd Earnings Yield 51.02%
FCF Yield -102.16%
Market Cap 1.51B Enterprise Value 6.89B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 6.06B 6.14B 5.98B 5.20B 5.54B
Net Income 471.89M 532.61M 604.81M -144.78M 706.59M
EPS (Diluted) 0.02 0.14 0.17 -0.04 0.22
Gross Profit 4.04B 4.20B 4.14B 3.40B 3.99B
Operating Income 1.29B 1.03B 1.21B 386.99M 1.42B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 29.61B 25.49B 24.25B 22.58B 20.63B
Total Liabilities 13.86B 11.96B 13.21B 13.47B 12.53B
Shareholders' Equity 14.15B 12.53B 10.18B 8.49B 7.89B
Total Debt 10.32B 8.42B 9.10B 9.49B 9.98B
Cash & Equivalents 4.94B 3.24B 2.32B 2.44B 3.87B
Current Assets 13.31B 10.70B 10.79B 10.40B 9.97B
Current Liabilities 10.77B 8.14B 9.49B 7.33B 7.23B